4DQSAR
Bluelighter
- Joined
- Feb 3, 2025
- Messages
- 5,458
Don't they put some of the money from the suits into other projects as well? If so it wouldn't be a complete waste of time.
I can't feel too bad for venture capitalists. So long as they haven't been lied to, due diligence and all that.
I've been told that venture capitalists expect three out of every five businesses they invest in will fail. But they immense profits the other two make more than offset the losses.
I just couldn't work at somewhere like GABA labs because it's a hiding to nothing. NOW what we MAY see is one or more of the senior researchers finding another use. I said before that I had proposed introducing the alcohol-mimic as a treatment for alcohol dependence. It totally stops AWS so certainly has utility but obviously that would be a much smaller market and they will have had to prodcing something novel, something that can be patented. I'm interested to see what (if anything) they come up with.
GABA Labs LTD applied for a UK patent in 2024 and 2025:
GB202504074D0
GB202403790D0
But there is no data to read. I think at this point it's worth noting that they bought three designs from us and applied for patents... but either didn't follow up OR the patent was refused. Could be the same things that a second application has been made for, could be a loophole homologue of same (we only offered three compounds - we didn't have the resources to make the thousands of homologues).
But I'm pretty confident they don't know the important bit - you need a compound that binds to ALL the a1 subunits. Not just the a1b1y2. We made them... but by that time we wanted nothing more to do with Nutt.
BTW one key detail is that it's generally accepted that you need at least 2 compounds to hit all three a1 subunits. So you have to test two compounds and how they might interact. We managed to do it with ONE. We didn't tell them how to do it ;-)
